000 | 01928 a2200541 4500 | ||
---|---|---|---|
005 | 20250516194550.0 | ||
264 | 0 | _c20140527 | |
008 | 201405s 0 0 eng d | ||
022 | _a2326-5205 | ||
024 | 7 |
_a10.1002/art.38241 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLambrecht, Stijn | |
245 | 0 | 0 |
_aGrowth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. _h[electronic resource] |
260 |
_bArthritis & rheumatology (Hoboken, N.J.) _cFeb 2014 |
||
300 |
_a418-27 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBiomarkers _xmetabolism |
650 | 0 | 4 |
_aBleomycin _xadverse effects |
650 | 0 | 4 |
_aChemokine CCL2 _xmetabolism |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aComorbidity |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 |
_aFibroblasts _xdrug effects |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 |
_aGrowth Differentiation Factor 15 _xdeficiency |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIn Vitro Techniques |
650 | 0 | 4 |
_aInterleukin-6 _xmetabolism |
650 | 0 | 4 | _aLongitudinal Studies |
650 | 0 | 4 |
_aLung _xdrug effects |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Knockout |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aPulmonary Fibrosis _xepidemiology |
650 | 0 | 4 |
_aScleroderma, Systemic _xchemically induced |
650 | 0 | 4 |
_aSkin Diseases _xepidemiology |
650 | 0 | 4 |
_aStromal Cells _xmetabolism |
700 | 1 | _aSmith, Vanessa | |
700 | 1 | _aDe Wilde, Katelijne | |
700 | 1 | _aCoudenys, Julie | |
700 | 1 | _aDecuman, Saskia | |
700 | 1 | _aDeforce, Dieter | |
700 | 1 | _aDe Keyser, Filip | |
700 | 1 | _aElewaut, Dirk | |
773 | 0 |
_tArthritis & rheumatology (Hoboken, N.J.) _gvol. 66 _gno. 2 _gp. 418-27 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.38241 _zAvailable from publisher's website |
999 |
_c23524153 _d23524153 |